The effect of a novel high-adherence weight loss programme in achieving weight loss and other health benefits

ISRCTN ISRCTN12421711
DOI https://doi.org/10.1186/ISRCTN12421711
Secondary identifying numbers eMed001
Submission date
16/10/2024
Registration date
21/10/2024
Last edited
21/10/2024
Recruitment status
No longer recruiting
Overall study status
Ongoing
Condition category
Nutritional, Metabolic, Endocrine
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English Summary

Background and study aims
This study (the “Study”) is designed to assess the effectiveness and acceptability of a novel weight management programme (the “Programme”). The Programme is structured around a mobile application, and aims to provide a high-adherence model of care, support and guidance to participants in order to lose weight. Participants may also be prescribed medication to support their weight loss efforts as part of the Programme where this is deemed clinically appropriate following individual clinical review.

Who can participate?
Adults between the ages of 18 and 65 who meet the eligibility criteria and live in England or Wales. Participants will agree to the normal terms of the Programme, including any monthly fee associated.

What does the study involve?
The Programme involves regular check-ins including weight, side effect monitoring, blood tests and questionnaires. This data will be collected and analyzed as part of this study to draw conclusions concerning the effectiveness and acceptability of the Programme.

What are the possible benefits and risks of participating?
The expected benefit is weight loss and reduction of the complications associated with obesity. In addition, participants will be supported during their journey.
Medications may be prescribed to patients as part of the Programme if this is considered to be appropriate following individual clinical review. Side effects and risks of any medication prescribed will be discussed with patients at the point of prescribing, and informed consent obtained.

Where is the study run from?
eMed Healthcare UK Ltd

When is the study starting and how long is it expected to run for?
October 2024 to December 2025

Who is funding the study?
eMed Healthcare UK Ltd

Who is the main contact?
Dr Matthew Noble, matthew.noble@emed.com

Contact information

Dr Matthew Noble
Public, Scientific, Principal Investigator

184-192 Drummond Street
London
NW1 3HP
United Kingdom

ORCiD logoORCID ID 0000-0003-1174-186X
Phone +44 330 303 8000
Email matthew.noble@emed.com

Study information

Study designDescriptive case series retrospective observational study in a single centre
Primary study designObservational
Secondary study designCase series
Study setting(s)Home
Study typeTreatment
Participant information sheet Not available in web format, please use contact details to request a participant information sheet
Scientific titleThe effect of and satisfaction with a novel high-adherence weight loss programme in achieving weight loss and other health benefits in adults with obesity: a retrospective observational study
Study acronymHAWLoP
Study hypothesisTo evaluate the effectiveness and acceptability of a novel high adherence weight management support programme.
Ethics approval(s)Ethics approval not required
Ethics approval additional informationThis is a retrospective observational study that does not involve any randomisation, treatment or management changes.
ConditionObesity
InterventionThis study is designed to assess the effectiveness and acceptability of a novel weight management programme (the “Programme”).

The Programme is structured around a mobile application, and aims to provide a high-adherence model of care, support and guidance to participants in order to lose weight. Participants may also be prescribed medication to support their weight loss efforts as part of the Programme where this is deemed clinically appropriate following individual clinical review. The Programme involves regular check-ins including weight, side effect monitoring, blood tests and questionnaires.

The Programme is already established and collects information on participation, outcomes, satisfaction, side effects, blood test data and other questionnaires as part of usual treatment. This study is designed to retrospectively analyze this routinely-collected data in order to draw conclusions concerning the effectiveness and acceptability of the Programme.

The duration of the study is six months. Patients will be followed up for a further six months.
Intervention typeMixed
Primary outcome measureBMI kg/m² measured using validated weight and self-reported height at baseline and validated weight and self-reported height at monthly intervals. Weight will be validated by directly observing the participant on a weighing-scale by video call.
Secondary outcome measures1. Patient satisfaction measured using the NHS "Friends and family test" question throughout the duration of the study
2. Frequency, severity and nature of adverse events and side effects measured using an internally-developed side-effect reporting questionnaire throughout the duration of the study
3. Engagement with programme components such as check-ins measured using internal data to determine the percentage of recommended programme activities that the patient completes throughout the study
4. Drop out rate and any reasons provided for leaving the Programme measured using patient self-reporting at the end of the study
5. Weight loss of participants compared to that described in evaluations of other programmes measured using validated weight measurements collected at baseline and at the end of the study
Overall study start date01/10/2024
Overall study end date31/12/2025

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
Upper age limit64 Years
SexBoth
Target number of participants1000
Participant inclusion criteriaPatients who took part in the Programme provided by the treatment centre
Participant exclusion criteriaDoes not meet inclusion criteria
Recruitment start date01/11/2024
Recruitment end date01/04/2025

Locations

Countries of recruitment

  • England
  • United Kingdom
  • Wales

Study participating centre

eMed Healthcare UK Ltd
184-192 Drummond Steet
London
NW1 3HP
United Kingdom

Sponsor information

eMed Healthcare UK Ltd
Industry

184-192 Drummond Street
London
NW1 3HP
England
United Kingdom

Phone +44 330 303 8000
Email charlie@emed.com
Website http://www.emed.com/uk

Funders

Funder type

Industry

eMed Healthcare UK Ltd

No information available

Results and Publications

Intention to publish date01/06/2025
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryPublished as a supplement to the results publication
Publication and dissemination planPlanned publication in a peer-reviewed journal
IPD sharing planThe datasets generated during and/or analysed during the current study will be published as a supplement to the results publication.

Editorial Notes

21/10/2024: Trial's existence confirmed by Science 37.